Gallstone lithotripsy.
Extracorporeal shock-wave lithotripsy (ESWL) has been applied to patients with gallstones since the mid-1980s. Lithotriptors differ by their means of shock-wave generation, the mechanisms by which they are coupled to the patient, and their imaging systems. Entry in most treatment protocols is limited to symptomatic patients with one to three radiolucent stones having a diameter of 30 mm or less and a functioning gallbladder according to oral cholecystography. Treatments are given on an out-patient basis using intravenous analgesia and include adjuvant bile acid therapy. Deaths have not been reported, and the incidence of serious complications, related to the presence of fragments in the biliary system, is low. The studies show that ESWL is a safe and effective treatment for patients with a single gallstone less than or equal to 20 mm in diameter, but the efficacy for larger single stones and multiple stones is poor. To date, the Food and Drug Administration has not approved lithotriptors for the treatment of gallstones in the United States.
Nahrwold
D L
DL
Department of Surgery, Northwestern University Medical School, Chicago, Illinois.
D017024:Chemotherapy, Adjuvant; D002635:Chenodeoxycholic Acid / Q000627:therapeutic use; D002769:Cholelithiasis / Q000628:therapy*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008096:Lithotripsy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D016896:Treatment Outcome; D014481:United States; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid